Pàgina inicial > Resultats de la cerca: Atallah, Ehab
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
10 p, 903.6 KB Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy / Perl, Alexander E. (University of Pennsylvania) ; Larson, Richard A (University of Chicago) ; Podoltsev, Nikolai A. (Yale School of Medicine) ; Strickland, Stephen (Vanderbilt-Ingram Cancer Center) ; Wang, Eunice S. (Roswell Park Comprehensive Cancer Center) ; Atallah, Ehab (Medical College of Wisconsin) ; Schiller, Gary J. (David Geffen School of Medicine at UCLA) ; Martinelli, Giovanni (IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" IRST S.r.l) ; Neubauer, Andreas (Universitätsklinikum Giessen und Marburg GmbH) ; Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ; Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ; Recher, Christian (Centre Hospitalier Universitaire de Toulouse. Institut Universitaire du Cancer de Toulouse Oncopole. Université de Toulouse 3 Paul Sabatier) ; Yoon, Sung-Soo (Seoul National University Hospital) ; Maeda, Yoshinobu (Okayama University Hospital) ; Hosono, Naoko (University of Fukui) ; Onozawa, Masahiro (Hokkaido University) ; Kato, Takayrasu (Department of Hematology. University of Tsukuba) ; Kim, Hee-Je (Catholic Hematology Hospital. College of Medicine. The Catholic University of Korea) ; Hasabou, Nahla (Astellas Pharma US. Inc.) ; Nuthethi, Rishita (Astellas Pharma US. Inc.) ; Tiu, Ramon (Astellas Pharma US. Inc.) ; Levis, Mark J. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University)
The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. [...]
2023 - 10.1016/j.jtct.2022.12.006
Transplantation and Cellular Therapy, Vol. 29 Núm. 4 (april 2023) , p. 265.e1-265.e10  
Registre complet - Creative Commons
2.
10 p, 1.1 MB Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial / Perl, Alexander E. (University of Pennsylvania) ; Larson, Richard A (University of Chicago) ; Podoltsev, Nikolai A. (Yale School of Medicine) ; Strickland, Stephen. (Vanderbilt-Ingram Cancer Center) ; Wang, Eunice S. (Roswell Park Comprehensive Cancer Center) ; Atallah, Ehab (Cancer Center-Froedtert Hospital) ; Schiller, Gary J. (David Geffen School of Medicine at UCLA) ; Martinelli, Giovanni (IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori,") ; Neubauer, Andreas (Universitätsklinikum Giessen und Marburg GmbH) ; Sierra, Jorge (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ; Récher, Christian (Centre Hospitalier Universitaire de Toulouse) ; Yoon, Sung Soo (Seoul National University Hospital) ; Hosono, Naoko (University of Fukui) ; Onozawa, Masahiro (Hokkaido University) ; Chiba, Shigeru (University of Tsukuba) ; Kim, Hee-Je (Catholic Hematology Hospital) ; Hasabou, Nahla (Astellas Pharma US. Inc) ; Lu, Qiaoyang (Astellas Pharma US. Inc) ; Tiu, Ramon (Astellas Pharma US. Inc) ; Levis, Mark (Johns Hopkins University) ; Universitat Autònoma de Barcelona. Departament de Medicina
The phase 3 ADMIRAL (NCT02421939; Study ID: 2215-CL-0301) trial showed superior overall survival in patients with relapsed/refractory FLT3-mutation-positive acute myeloid leukemia (AML) randomized 2:1 to receive the oral FMS-like tyrosine kinase 3 inhibitor gilteritinib vs those randomized to receive salvage chemotherapy (SC). [...]
2022 - 10.1182/blood.2021011583
Blood, Vol. 139 Núm. 23 (june 2022) , p. 3366-3375  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem